Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review Export

@article{citeulike:2591541, abstract = {Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.}, author = {Warren, Oliver and Mandal, Kaushik and Hadjianastassiou, Vassilis and Knowlton, Lisa and Panesar, Sukhmeet and John, Kokotsakis and Darzi, Ara and Athanasiou, Thanos}, citeulike-article-id = {2591541}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.athoracsur.2006.10.033}, citeulike-linkout-1 = {http://www.sciencedirect.com/science/article/B6T11-4MWPM77-30/2/a651f7ce7aaf6a47d50a5012e75f490d}, doi = {10.1016/j.athoracsur.2006.10.033}, journal = {The Annals of Thoracic Surgery}, keywords = {factor-viia, haemostasis}, month = {February}, number = {2}, pages = {707--714}, posted-at = {2008-03-26 11:50:58}, priority = {2}, title = {Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review}, url = {http://dx.doi.org/10.1016/j.athoracsur.2006.10.033}, volume = {83}, year = {2007} }

TY - JOUR ID - citeulike:2591541 L3 - citeulike-article-id:2591541 N2 - Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient. IS - 2 JF - The Annals of Thoracic Surgery EP - 714 TI - Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review VL - 83 SP - 707 KW - factor-viia KW - haemostasis AU - Warren, Oliver AU - Mandal, Kaushik AU - Hadjianastassiou, Vassilis AU - Knowlton, Lisa AU - Panesar, Sukhmeet AU - John, Kokotsakis AU - Darzi, Ara AU - Athanasiou, Thanos PY - 2007/02// UR - http://dx.doi.org/10.1016/j.athoracsur.2006.10.033 ER -